Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with type 1 autoimmune hepatitis in Japanese

  1. Takeji Umemura1,*,
  2. Masao Ota2,
  3. Kaname Yoshizawa1,
  4. Yoshihiko Katsuyama3,
  5. Tetsuya Ichijo1,
  6. Eiji Tanaka1,
  7. Kendo Kiyosawa1

Article first published online: 25 MAR 2008

DOI: 10.1111/j.1872-034X.2008.00337.x

Issue

Hepatology Research

Hepatology Research

Volume 38, Issue 7, pages 689–695, July 2008

Additional Information

How to Cite

Umemura, T., Ota, M., Yoshizawa, K., Katsuyama, Y., Ichijo, T., Tanaka, E. and Kiyosawa, K. (2008), Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with type 1 autoimmune hepatitis in Japanese. Hepatology Research, 38: 689–695. doi: 10.1111/j.1872-034X.2008.00337.x

Author Information

  1. 1

    Department of Internal Medicine, Divisions of Gastroenterology and Hepatology,

  2. 2

    Legal Medicine and

  3. 3

    Pharmacy, Shinshu University School of Medicine, Matsumoto, Japan

*Dr Takeji Umemura, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan. Email: t-ume@hsp.md.shinshu-u.ac.jp

Publication History

  1. Issue published online: 25 MAR 2008
  2. Article first published online: 25 MAR 2008
  3. Received 13 November 2007; revision 15 December 2007; accepted 8 January 2008.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (81K)

Keywords:

  • autoimmune hepatitis;
  • CTLA4;
  • genetic susceptibility;
  • SNPs

Aim:  Autoimmune hepatitis (AIH) is an organ-specific autoimmune disease characterized by chronic inflammation of the liver. Although the HLA DR4 allele is associated with type 1 AIH in Japanese, the exact genetic etiology of AIH remains undefined. The cytotoxic T-lymphocyte antigen 4 (CTLA4) is an inhibitory receptor expressed by T-cells that acts largely as a negative regulator of T-cell responses, and polymorphisms of CTLA4 have been reported to be associated with susceptibility to various autoimmune diseases. Therefore, we sought to clarify whether CTLA4 single-nucleotide polymorphisms are associated with disease susceptibility in Japanese patients with type 1 AIH.

Methods:  We genotyped 76 patients with AIH and 100 ethically matched controls for allelic determinants using TaqMan genotyping assays at four polymorphism sites: −1722 and −318 in the promoter; +49 in exon 1 and +6230 in the 3′ untranslated region.

Results:  We observed no difference in the distribution of the alleles, genotypes, or haplotypes between patients and controls. Compared with −1722 C/C patients, −1722 T/T patients were younger (56 vs. 63 years; P = 0.01) and had significantly lower serum levels of aspartate aminotransferase (313 vs. 763 IU/L; P = 0.031) and bilirubin (1.1 vs. 8.6 mg/dL; P = 0.027). Analysis of allelic frequencies revealed no significant difference between patients with and without the HLA DR4 allele.

Conclusion:  These data suggest that the CTLA4 polymorphism is not associated with susceptibility to type 1 AIH in the Japanese population.

View Full Article (HTML) Get PDF (81K)